May 2021

In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…

LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announces that it has made the decision to return the COVID-related relief funding it received in both the Netherlands and the United States. During 2020, LUMICKS received a total…